<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732160</url>
  </required_header>
  <id_info>
    <org_study_id>080248</org_study_id>
    <nct_id>NCT00732160</nct_id>
  </id_info>
  <brief_title>Aldosterone and Glucose Homeostasis</brief_title>
  <official_title>Aldosterone and Glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the effect of aldosterone on how the body handles glucose (sugar).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the effect of aldosterone on glucose metabolism in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>3 hours</time_frame>
    <description>Acute Insulin response during Hyperglycemic clamp (delta insulin uU/mL, t=0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>3 hours</time_frame>
    <description>Insulin sensitivity index (ISI) was calculated by dividing the average glucose infusion rate (mg glucose infusion/kg body weight/min) by the average insulin concentration (uU/mL) from 90 to 120 minutes. This was multiplied by 100 (thus, x100 in units description), per reporting convention in literature.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HS-V/A; LS-V/A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-A/V; LS-A/V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LS-V/A; HS-V/A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LS-A/V; HS-A/V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldosterone infusion (A)</intervention_name>
    <description>Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)</description>
    <arm_group_label>HS-V/A; LS-V/A</arm_group_label>
    <arm_group_label>HS-A/V; LS-A/V</arm_group_label>
    <arm_group_label>LS-V/A; HS-V/A</arm_group_label>
    <arm_group_label>LS-A/V; HS-A/V</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Infusion (V)</intervention_name>
    <description>Vehicle infusion for 12.5 hours</description>
    <arm_group_label>HS-V/A; LS-V/A</arm_group_label>
    <arm_group_label>HS-A/V; LS-A/V</arm_group_label>
    <arm_group_label>LS-V/A; HS-V/A</arm_group_label>
    <arm_group_label>LS-A/V; HS-A/V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Sodium Diet (HS)</intervention_name>
    <description>160 mmol/d sodium diet for 7 days</description>
    <arm_group_label>HS-V/A; LS-V/A</arm_group_label>
    <arm_group_label>HS-A/V; LS-A/V</arm_group_label>
    <arm_group_label>LS-V/A; HS-V/A</arm_group_label>
    <arm_group_label>LS-A/V; HS-A/V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Sodium Diet (LS)</intervention_name>
    <description>20 mmol/d sodium diet for 9 days</description>
    <arm_group_label>HS-V/A; LS-V/A</arm_group_label>
    <arm_group_label>HS-A/V; LS-A/V</arm_group_label>
    <arm_group_label>LS-V/A; HS-V/A</arm_group_label>
    <arm_group_label>LS-A/V; HS-A/V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory subjects, 18 to 70 years of age, inclusive

          2. For female subjects, the following conditions must be met:

             a postmenopausal status for at least 1 year, or b status-post surgical sterilization,
             or c if of childbearing potential, utilization of adequate birth control and
             willingness to undergo urine beta-hcg testing prior to drug treatment and on every
             study day

          3. Metabolic Syndrome as defined by the presence of &gt; 3 of the following:

        a Systolic Blood Pressure &gt; 130 mm Hg OR Diastolic Blood Pressure &gt; 85 mm Hg. b Glucose
        Intolerance (Fasting Plasma Glucose &gt; 100 mg/dL) c Increased triglyceride level &gt; 150mg/dL
        (1.7mmol/L) d Decreased levels of HDL cholesterol For males, less than 40 mg/dL For
        females, less than 50 mg/dL e Waist circumference For males, greater than 40 inches (102
        cm) For females, greater than 35 inches (89 cm).

        Exclusion Criteria:

          1. Previously diagnosed Type I Diabetes , or the use of anti-diabetic medication.
             Subjects with type II diabetes not on medication will be allowed to participate if
             fasting blood glucose is &lt;200mg/dL.

          2. Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium
             chloride).

          3. Screening plasma potassium &lt;3.5 mmol/L or use of chronic potassium supplements for the
             treatment of hypokalemia

          4. Use of hormone replacement therapy

          5. If on statin therapy for hypercholesterolemia, a change in dose within the past 6
             months.

          6. Breast-feeding

          7. Cardiovascular disease such as prior myocardial infarction, presence of angina
             pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy
             acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart
             block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy

          8. Treatment with anticoagulants

          9. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or
             transient ischemic attack

         10. History or presence of immunological or hematological disorders

         11. Diagnosis of asthma requiring use of inhaled beta agonist &gt;1 time per week

         12. Clinically significant gastrointestinal impairment that could interfere with drug
             absorption

         13. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino
             transaminase (ALT) &gt;2.0 x upper limit of normal range]

         14. Impaired renal function [estimated glomerular filtration rate (eGFR) of &lt;60ml/min] as
             determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation,
             where serum creatinine (Scr) is expressed in mg/dl and age in years:

         15. eGFR &lt;60 ml/min

         16. Hematocrit &lt;35%

         17. Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult, such as arthritis treated with non-steroidal
             antiinflammatory drugs

         18. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days
             in 1 month)

         19. Treatment with lithium salts

         20. History of alcohol or drug abuse

         21. Treatment with any investigational drug in the 1 month preceding the study

         22. Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

         23. Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Luther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>May 8, 2015</results_first_submitted>
  <results_first_submitted_qc>February 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2017</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>James Matt Luther</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Glucose</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>11 participants did not start the study (5 Participants did Not Meet inclusion or exclusion criteria, 6 declined participation)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HS-V/A; LS-V/A</title>
          <description>High Sodium diet- Vehicle then Aldosterone Low Sodium diet- Vehicle then Aldosterone</description>
        </group>
        <group group_id="P2">
          <title>HS-A/V; LS-A/V</title>
          <description>High Sodium diet- Aldosterone then Vehicle Low Sodium diet- Aldosterone then Vehicle</description>
        </group>
        <group group_id="P3">
          <title>LS-V/A; HS-V/A</title>
          <description>Low Sodium diet- Vehicle then Aldosterone High Sodium diet- Vehicle then Aldosterone</description>
        </group>
        <group group_id="P4">
          <title>LS-A/V; HS-A/V</title>
          <description>Low Sodium diet- Aldosterone then Vehicle High Sodium diet- Aldosterone then Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HS Vehicle</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HS Aldosterone</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>LS Vehicle</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>LS Aldosterone</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>scheduling</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy volunteers</population>
      <group_list>
        <group group_id="B1">
          <title>HS-V/A; LS-V/A</title>
          <description>High Sodium diet- Vehicle then Aldosterone Low Sodium diet- Vehicle then Aldosterone</description>
        </group>
        <group group_id="B2">
          <title>HS-A/V; LS-A/V</title>
          <description>High Sodium diet- Aldosterone then Vehicle Low Sodium diet- Aldosterone then Vehicle</description>
        </group>
        <group group_id="B3">
          <title>LS-V/A; HS-V/A</title>
          <description>Low Sodium diet- Vehicle then Aldosterone High Sodium diet- Vehicle then Aldosterone</description>
        </group>
        <group group_id="B4">
          <title>LS-A/V; HS-A/V</title>
          <description>Low Sodium diet- Aldosterone then Vehicle High Sodium diet- Aldosterone then Vehicle</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" lower_limit="21.7" upper_limit="30.1"/>
                    <measurement group_id="B2" value="29.2" lower_limit="24.5" upper_limit="36.5"/>
                    <measurement group_id="B3" value="32.5" lower_limit="20.9" upper_limit="47.5"/>
                    <measurement group_id="B4" value="27.2" lower_limit="20.8" upper_limit="30.8"/>
                    <measurement group_id="B5" value="28.4" lower_limit="20.8" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose (mg/dL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.3" spread="7.6"/>
                    <measurement group_id="B2" value="85.4" spread="7.2"/>
                    <measurement group_id="B3" value="85.3" spread="7.6"/>
                    <measurement group_id="B4" value="85.4" spread="7.2"/>
                    <measurement group_id="B5" value="85.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion</title>
        <description>Acute Insulin response during Hyperglycemic clamp (delta insulin uU/mL, t=0-10)</description>
        <time_frame>3 hours</time_frame>
        <population>Three subjects were excluded or withdrew after infusion but before hyperglycemic clamp due to low potassium, loss of IV access, burning at IV site. These 3 participants were not included in final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle, HS</title>
            <description>Vehicle Infusion, High Salt diet</description>
          </group>
          <group group_id="O2">
            <title>Vehicle, LS</title>
            <description>Vehicle Infusion, Low Salt diet</description>
          </group>
          <group group_id="O3">
            <title>Aldosterone, HS</title>
            <description>Aldosterone Infusion, High Salt diet</description>
          </group>
          <group group_id="O4">
            <title>Aldosterone, LS</title>
            <description>Aldosterone Infusion, Low Salt diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion</title>
          <description>Acute Insulin response during Hyperglycemic clamp (delta insulin uU/mL, t=0-10)</description>
          <population>Three subjects were excluded or withdrew after infusion but before hyperglycemic clamp due to low potassium, loss of IV access, burning at IV site. These 3 participants were not included in final analysis.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="34.8"/>
                    <measurement group_id="O2" value="37.6" spread="30.9"/>
                    <measurement group_id="O3" value="51.8" spread="40.2"/>
                    <measurement group_id="O4" value="34.4" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Insulin sensitivity index (ISI) was calculated by dividing the average glucose infusion rate (mg glucose infusion/kg body weight/min) by the average insulin concentration (uU/mL) from 90 to 120 minutes. This was multiplied by 100 (thus, x100 in units description), per reporting convention in literature.</description>
        <time_frame>3 hours</time_frame>
        <population>Three subjects were excluded or withdrew after infusion but before hyperglycemic clamp due to low potassium, loss of IV access, burning at IV site. These 3 participants were not included in final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle, HS</title>
            <description>Vehicle Infusion, High Salt diet</description>
          </group>
          <group group_id="O2">
            <title>Vehicle, LS</title>
            <description>Vehicle Infusion, Low Salt diet</description>
          </group>
          <group group_id="O3">
            <title>Aldosterone, HS</title>
            <description>Aldosterone Infusion, High Salt diet</description>
          </group>
          <group group_id="O4">
            <title>Aldosterone, LS</title>
            <description>Aldosterone Infusion, Low Salt diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity index (ISI) was calculated by dividing the average glucose infusion rate (mg glucose infusion/kg body weight/min) by the average insulin concentration (uU/mL) from 90 to 120 minutes. This was multiplied by 100 (thus, x100 in units description), per reporting convention in literature.</description>
          <population>Three subjects were excluded or withdrew after infusion but before hyperglycemic clamp due to low potassium, loss of IV access, burning at IV site. These 3 participants were not included in final analysis.</population>
          <units>mg/kg/min per uU/mL*100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="15.4"/>
                    <measurement group_id="O2" value="24.8" spread="16.4"/>
                    <measurement group_id="O3" value="23.4" spread="17.3"/>
                    <measurement group_id="O4" value="24.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vehicle, HS</title>
          <description>Vehicle Infusion, High Salt diet</description>
        </group>
        <group group_id="E2">
          <title>Vehicle, LS</title>
          <description>Vehicle Infusion, Low Salt diet</description>
        </group>
        <group group_id="E3">
          <title>Aldosterone, HS</title>
          <description>Aldosterone Infusion, High Salt diet</description>
        </group>
        <group group_id="E4">
          <title>Aldosterone, LS</title>
          <description>Aldosterone Infusion, Low Salt diet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>IV site discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion or rhinorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Low potassium</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <description>during study diet, prior to drug infusion</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James M. Luther</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 936-3420</phone>
      <email>James.Luther@Vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

